Codexis (CDXS) Non-Current Deffered Revenue (2010 - 2026)
Codexis (CDXS) recorded quarterly Non-Current Deffered Revenue of $350000.0 in Q1 2026, down 2.78% quarter-over-quarter from $360000.0 in Q4 2025, and down 28.57% on a YoY basis from $490000.0 in Q1 2025.
Codexis (CDXS) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Codexis' Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $350000.0 for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 28.57% year-over-year to $350000.0; the TTM figure through Mar 2026 stood at $350000.0 (down 28.57% YoY), while the FY2025 annual figure was $360000.0, up 260.0% from the prior year.
- Non-Current Deffered Revenue was $350000.0 for Q1 2026 at Codexis, down from $360000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $16.9 million in Q4 2022 to a low of $100000.0 in Q4 2024.
- Historically, Non-Current Deffered Revenue has averaged $4.2 million across 5 years, with a median of $630000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue jumped 350.28% in 2022, then tumbled 98.02% in 2024.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $16.9 million in 2022, then sank by 96.21% to $640000.0 in 2023, then tumbled by 84.38% to $100000.0 in 2024, then soared by 260.0% to $360000.0 in 2025, then declined by 2.78% to $350000.0 in 2026.
- The last three Non-Current Deffered Revenue figures came in at $350000.0 (Q1 2026), $360000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Codexis | 236.00 Mn | 170.86 Mn | 13.18 Mn | 350,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 350,000.00 |
| Dec 31, 2025 | 360,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 490,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 630,000.00 |
| Dec 31, 2023 | 640,000.00 |
| Sep 30, 2023 | 10.10 Mn |
| Jun 30, 2023 | 10.11 Mn |
| Mar 31, 2023 | 15.51 Mn |
| Dec 31, 2022 | 16.88 Mn |
| Sep 30, 2022 | 8.24 Mn |
| Jun 30, 2022 | 3.15 Mn |
| Mar 31, 2022 | 3.46 Mn |
| Dec 31, 2021 | 3.75 Mn |
| Sep 30, 2021 | 3.75 Mn |
| Jun 30, 2021 | 3.17 Mn |